Abstract
There is an increased risk of osteoporosis and an abnormal bone turn over in neurofibromatosis 1 (NF1). Our objective is to evaluate bone status in NF1 and to look for associations with cutaneous phenotype. We conducted a descriptive, monocentric study. We included 60 NF1 women, 18–51 years old, non-menopausal, divided in 2 groups: «at risk phenotype» (ARP) composed by 30 patients with at least 2 subcutaneous neurofibromas (SC-NF) and «classical phenotype» (CP) composed by 30 patients with none or 1 SC-NF. We evaluated low bone mineral density (BMD) risk factors and measured BMD, calcium and phosphorus homeostasis and bone turnover markers. Before 50 years old, Z-score has to be used to assess BMD. Z-score < − 2 is below expected range and represents 2.5% of the population. There was no difference between the two groups. Overall, Z-scores were low and 5 patients had a Z-score < − 2 (8.3%), which is 3 times general population low BMD frequency. 10 fragility fractures occurred in 8 patients, among which 2 were vertebral fractures. 85% had low calcium intake. 12 patients had hypophosphoremia, 25 elevated PTH. Vitamin D levels were low for 86.4%. 41 patients (69.5%) had at least one abnormal bone turnover markers. Low BMD is 3.3 times more frequent in NF1 than in general population, with high fracture risk, regardless of the skin phenotype, classical or at risk, because of high bone turn over and secondary hyperparathyroidism due to vitamin D deficiency and poor calcium intake.
Similar content being viewed by others
References
Uusitalo E, Leppävirta J, Koffert A, Suominen S, Vahtera J, Vahlberg T et al (2015) Incidence and mortality of neurofibromatosis: a total population study in Finland. J Investig Dermatol 135(3):904–906
Hirbe AC, Gutmann DH (2014) Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 13(8):834–843
Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ (2017) Neurofibromatosis type 1. Nat Rev Dis Primer 23(3):17004
The National Institutes of Health (NIH) Consensus Development Program: neurofibromatosis [Internet]. [cited 2018 Apr 17]. https://consensus.nih.gov/1987/1987Neurofibramatosis064html.htm
Pinson S, Wolkenstein P (2005) Neurofibromatosis type 1 or Von Recklinghausen’s disease. Rev Med Interne 26(3):196–215
Cunha KSG, Caruso AC, de Faria PAS, da Silva LE, Pires ARC, Geller M et al (2012) Malignant peripheral nerve sheath tumors: clinicopathological aspects, expression of p53 and survival. Clinics 67(8):963–968
Khosrotehrani K, Bastuji-Garin S, Zeller J, Revuz J, Wolkenstein P (2003) Clinical risk factors for mortality in patients with neurofibromatosis 1: a cohort study of 378 patients. Arch Dermatol 139(2):187–191
Poyrazoğlu HG, Baş VN, Arslan A, Bastug F, Canpolat M, Per H et al (2017) Bone mineral density and bone metabolic markers’ status in children with neurofibromatosis type 1. J Pediatr Endocrinol Metab 30(2):175–180
Yilmaz K, Ozmen M, Bora Goksan S, Eskiyurt N (2007) Bone mineral density in children with neurofibromatosis 1. Acta Paediatr Oslo Nor 1992 96(8):1220–2
Stevenson DA, Moyer-Mileur LJ, Murray M, Slater H, Sheng X, Carey JC et al (2007) Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 150(1):83–88
Dulai S, Briody J, Schindeler A, North KN, Cowell CT, Little DG (2007) Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J Pediatr Orthop 27(4):472–475
Lammert M, Kappler M, Mautner V-F, Lammert K, Störkel S, Friedman JM et al (2005) Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 16(9):1161–1166
Tucker T, Schnabel C, Hartmann M, Friedrich RE, Frieling I, Kruse H-P et al (2009) Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet 46(4):259–265
Heervä E, Koffert A, Jokinen E, Kuorilehto T, Peltonen S, Aro HT et al (2012) A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age. J Bone Miner Res 27(11):2333–2337
Heervä E, Leinonen P, Kuorilehto T, Peltonen S, Pöyhönen M, Väänänen K et al (2013) Neurofibromatosis 1-related osteopenia often progresses to osteoporosis in 12 years. Calcif Tissue Int 92(1):23–27
Heervä E, Alanne MH, Peltonen S, Kuorilehto T, Hentunen T, Väänänen K et al (2010) Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. Bone 47(3):583–590
Schindeler A, Little DG (2008) Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone 42(4):616–622
Seitz S, Schnabel C, Busse B, Schmidt HU, Beil FT, Friedrich RE et al (2010) High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos Int 21(1):119–127
Brunetti-Pierri N, Doty SB, Hicks J, Phan K, Mendoza-Londono R, Blazo M et al (2008) Generalized metabolic bone disease in neurofibromatosis type I. Mol Genet Metab 94(1):105–111
Lammert M, Friedman JM, Roth HJ, Friedrich RE, Kluwe L, Atkins D et al (2006) Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis 1. J Med Genet 43(10):810–813
Petramala L, Giustini S, Zinnamosca L, Marinelli C, Colangelo L, Cilenti G et al (2012) Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease). Arch Dermatol Res 304(4):325–331
Schnabel C, Dahm S, Streichert T, Thierfelder W, Kluwe L, Mautner VF (2014) Differences of 25-hydroxyvitamin D3 concentrations in children and adults with neurofibromatosis type 1. Clin Biochem 47(7–8):560–563
Souza Mario Bueno L, Rosset C, Aguiar E, Pereira F de S, Izetti Ribeiro P, Scalco R et al (2015) Vitamin D status and VDR genotype in NF1 patients: a case-control study from Southern Brazil. Int J Endocrinol 2015:1–9
Hockett CW, Eelloo J, Huson SM, Roberts SA, Berry JL, Chaloner C et al (2013) Vitamin D status and muscle function in children with neurofibromatosis type 1 (NF1). J Musculoskelet Neuronal Interact 13(1):111–119
Schnabel C, Jett K, Friedman JM, Frieling I, Kruse H-P, Mautner V (2013) Effect of vitamin D3 treatment on bone density in neurofibromatosis 1 patients: a retrospective clinical study. Jt Bone Spine 80(3):315–319
Fardellone P, Sebert JL, Bouraya M, Bonidan O, Leclercq G, Doutrellot C et al (1991) Evaluation of the calcium content of diet by frequential self-questionnaire. Rev Rhum Mal Osteoartic 58(2):99–103
Roux C, Briot K, Dumarcet N, Bourgoin M, Chapurlat R, Christin-Maitre S et al (2006) Traitement médicamenteux de l’ostéoporose post-ménopausique. Presse Médicale 35(10):1529–1539
Souberbielle J-C, Cavalier E, Delanaye P, Massart C, Brailly-Tabard S, Cormier C et al (2015) Serum calcitriol concentrations measured with a new direct automated assay in a large population of adult healthy subjects and in various clinical situations. Clin Chim Acta Int J Clin Chem 451(Pt B):149–153
Lewiecki EM, Gordon CM, Baim S, Binkley N, Bilezikian JP, Kendler DL et al (2008) Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 19(10):1369–1378
Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D et al (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res Off J Am Soc Bone Miner Res 11(7):984–996
Koga M, Yoshida Y, Imafuku S (2016) Nutritional, muscular and metabolic characteristics in patients with neurofibromatosis type 1. J Dermatol 43(7):799–803
Chiffres du tabac/Vos questions/Nos reponses/Accueil-tabac-info-service.fr [Internet]. [cited 2020 Sep 4]. https://www.tabac-info-service.fr/Vos-questions-Nos-reponses/Chiffres-du-tabac
Gupta A, Dwivedi A, Patel P, Gupta S (2015) Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis: case report and literature review. Indian J Radiol Imaging 25(1):63–66
Konishi K, Nakamura M, Yamakawa H, Suzuki H, Saruta T, Hanaoka H et al (1991) Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis. Am J Med Sci 301(5):322–328
Souberbielle J-C (2016) Epidemiology of vitamin-D deficiency. Geriatr Psychol Neuropsychiatr Vieil 1(14):7–15
Stevenson DA, Schwarz EL, Viskochil DH, Moyer-Mileur LJ, Murray M, Firth SD et al (2008) Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysis. Pediatr Res 63(6):697–701
Heervä E, Huilaja L, Leinonen P, Peltonen S, Peltonen J (2014) Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months. Calcif Tissue Int 94(6):608–612
Benlidayi IC, Ortac EA, Kozanoglu E (2015) Risedronate therapy for neurofibromatosis Type 1-related low bone mass: a stitch in time saves nine. Acta Clin Belg 70(2):130–132
Heervä E, Peltonen S, Svedström E, Aro HT, Väänänen K, Peltonen J (2012) Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. Bone 50(3):798–803
Rietman AB, Oostenbrink R, Bongers S, Gaukema E, van Abeelen S, Hendriksen JG et al (2017) Motor problems in children with neurofibromatosis type 1. J Neurodev Disord 9:19
Summers MA, Rupasinghe T, Vasiljevski ER, Evesson FJ, Mikulec K, Peacock L et al (2018) Dietary intervention rescues myopathy associated with neurofibromatosis type 1. Hum Mol Genet 27(4):577–88
Elefteriou F, Kolanczyk M, Schindeler A, Viskochil DH, Hock JM, Schorry EK et al (2009) Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A 149A(10):2327–2338
Pecoraro A, Arehart E, Gallentine W, Radtke R, Smith E, Pizoli C et al (2017) Epilepsy in neurofibromatosis type 1. Epilepsy Behav EB 73:137–141
Abdolrahimzadeh B, Piraino DC, Albanese G, Cruciani F, Rahimi S (2016) Neurofibromatosis: an update of ophthalmic characteristics and applications of optical coherence tomography. Clin Ophthalmol Auckl NZ 13(10):851–860
Funding
Funding was provided by Association Neurofibromatoses et von recklinghausen (Grant No. 45500euros).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
Maud Jalabert, Salah Ferkal, Arthur Mageau, Laurence Allanore, Philippe Le Corvoisier, Florent Eymard, Emilie Sbidian declare that they have no conflict of interest. Xavier Chevalier declare he have conflict of interest with IBSA, Flexion Therapics, Pfizer, Sanofi and Nordic Pharma. Pierre Wolkenstein declare he have conflict of interest with AstraZeneca, Springworks, Laboratoire d’Uriage, Pierre Fabre Dermatologie. J.C. Souberbielle declare he have conflict of interest with DiaSorin, Roche diagnostics, Mylan, MSD, Lily, Effik, Iprad Pharma, Yoplait.
Human and Animal Rights and Informed Consent
All animal procedures were approved by the national French ethical committee.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jalabert, M., Ferkal, S., Souberbielle, JC. et al. Bone Status According to Neurofibromatosis Type 1 Phenotype: A Descriptive Study of 60 Women in France. Calcif Tissue Int 108, 738–745 (2021). https://doi.org/10.1007/s00223-021-00807-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-021-00807-6